Literature DB >> 22178059

MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans.

Ming Zhang1, Yunfang Joan Hou, Erdal Cavusoglu, Daniel C Lee, Rudi Steffensen, Liming Yang, Daniel Bashari, Jose Villamil, Motaz Moussa, George Fernaine, Jens C Jensenius, Jonathan D Marmur, Wilson Ko, Ketan Shevde.   

Abstract

BACKGROUND/
OBJECTIVES: Insufficient blood supply to the heart results in ischemic injury manifested clinically as myocardial infarction (MI). Following ischemia, inflammation is provoked and related to the clinical outcomes. A recent basic science study indicates that complement factor MASP-2 plays an important role in animal models of ischemia/reperfusion injury. We investigated the role of MASP-2 in human acute myocardial ischemia in two clinical settings: (1) Acute MI, and (2) Open heart surgery.
METHODS: A total of 187 human subjects were enrolled in this study, including 50 healthy individuals, 27 patients who were diagnosed of coronary artery disease (CAD) but without acute MI, 29 patients with acute MI referred for coronary angiography, and 81 cardiac surgery patients with surgically-induced global heart ischemia. Circulating MASP-2 levels were measured by ELISA.
RESULTS: MASP-2 levels in the peripheral circulation were significantly reduced in MI patients compared with those of healthy individuals or of CAD patients without acute MI. The hypothesis that MASP-2 was activated during acute myocardial ischemia was evaluated in cardiac patients undergoing surgically-induced global heart ischemia. MASP-2 was found to be significantly reduced in the coronary circulation of such patients, and the reduction of MASP-2 levels correlated independently with the increase of the myocardial necrosis marker, cardiac troponin I.
CONCLUSIONS: These results indicate an involvement of MASP-2 in ischemia-related necrotic myocardial injury in humans.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178059      PMCID: PMC3310957          DOI: 10.1016/j.ijcard.2011.11.032

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  54 in total

1.  Open heart surgery in the elderly: results from a consecutive series of 100 patients aged 85 years or older.

Authors:  Todd K Rosengart; Eileen B Finnin; David Y Kim; Sanjay A Samy; Yvette Tanhehco; Wilson Ko; Samuel J Lang; Karl H Krieger; O Wayne Isom
Journal:  Am J Med       Date:  2002-02-01       Impact factor: 4.965

2.  Usefulness of cardiac troponin I in patients undergoing open heart surgery.

Authors:  N Greenson; J Macoviak; P Krishnaswamy; R Morrisey; C James; P Clopton; R Fitzgerald; A S Maisel
Journal:  Am Heart J       Date:  2001-03       Impact factor: 4.749

3.  Control of the classical and the MBL pathway of complement activation.

Authors:  S V Petersen; S Thiel; L Jensen; T Vorup-Jensen; C Koch; J C Jensenius
Journal:  Mol Immunol       Date:  2000-10       Impact factor: 4.407

4.  Proteolytic activities of two types of mannose-binding lectin-associated serine protease.

Authors:  M Matsushita; S Thiel; J C Jensenius; I Terai; T Fujita
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

5.  Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass.

Authors:  Akif Undar; Harald C Eichstaedt; Fred J Clubb; Michael Fung; Meisheng Lu; Joyce E Bigley; William K Vaughn; Charles D Fraser
Journal:  Ann Thorac Surg       Date:  2002-08       Impact factor: 4.330

Review 6.  The role of mannose-binding lectin in health and disease.

Authors:  M W Turner
Journal:  Mol Immunol       Date:  2003-11       Impact factor: 4.407

7.  Functional characterization of the lectin pathway of complement in human serum.

Authors:  Anja Roos; Lee H Bouwman; Jeric Munoz; Tahlita Zuiverloon; Maria C Faber-Krol; Francien C Fallaux-van den Houten; Ngaisah Klar-Mohamad; C Erik Hack; Marcel G Tilanus; Mohamed R Daha
Journal:  Mol Immunol       Date:  2003-01       Impact factor: 4.407

8.  Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals.

Authors:  Mette Møller-Kristensen; Jens Chr Jensenius; Lisbeth Jensen; Nicole Thielens; Véronique Rossi; Gerard Arlaud; Steffen Thiel
Journal:  J Immunol Methods       Date:  2003-11       Impact factor: 2.303

Review 9.  The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes.

Authors:  Wilhelm Schwaeble; Mads R Dahl; Steffen Thiel; Cordula Stover; Jens C Jensenius
Journal:  Immunobiology       Date:  2002-09       Impact factor: 3.144

10.  Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury.

Authors:  Wilhelm J Schwaeble; Nicholas J Lynch; James E Clark; Michael Marber; Nilesh J Samani; Youssif Mohammed Ali; Thomas Dudler; Brian Parent; Karl Lhotta; Russell Wallis; Conrad A Farrar; Steven Sacks; Haekyung Lee; Ming Zhang; Daisuke Iwaki; Minoru Takahashi; Teizo Fujita; Clark E Tedford; Cordula M Stover
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

View more
  17 in total

1.  Circulating lectin pathway proteins do not predict short-term cardiac outcomes after myocardial infarction.

Authors:  C B Holt; J A Østergaard; S Thiel; T K Hansen; L Mellbin; P Sörensson; M Bjerre
Journal:  Clin Exp Immunol       Date:  2019-06-03       Impact factor: 4.330

2.  Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases.

Authors:  V Frauenknecht; S Thiel; L Storm; N Meier; M Arnold; J-P Schmid; H Saner; V Schroeder
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

3.  Phospholipid scramblase 1 is required for β2-glycoprotein I binding in hypoxia and reoxygenation-induced endothelial inflammation.

Authors:  Emily Archer Slone; Michael R Pope; Sherry D Fleming
Journal:  J Leukoc Biol       Date:  2015-07-27       Impact factor: 4.962

Review 4.  Complement activation and cardiac surgery: a novel target for improving outcomes.

Authors:  Gregory L Stahl; Stanton K Shernan; Peter K Smith; Jerrold H Levy
Journal:  Anesth Analg       Date:  2012-07-13       Impact factor: 5.108

5.  Association of MASP-2 levels and MASP2 gene polymorphisms with rheumatoid arthritis in patients and their relatives.

Authors:  Isabela Goeldner; Thelma Skare; Angelica B W Boldt; Flavia R Nass; Iara J Messias-Reason; Shirley R Utiyama
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

Review 6.  The lectin pathway of complement and rheumatic heart disease.

Authors:  Marcia Holsbach Beltrame; Sandra Jeremias Catarino; Isabela Goeldner; Angelica Beate Winter Boldt; Iara José de Messias-Reason
Journal:  Front Pediatr       Date:  2015-01-21       Impact factor: 3.418

7.  Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury.

Authors:  Nicholas Chun; Ala S Haddadin; Junying Liu; Yunfang Hou; Karen A Wong; Daniel Lee; Julie I Rushbrook; Karan Gulaya; Roberta Hines; Tamika Hollis; Beatriz Nistal Nuno; Abeel A Mangi; Sabet Hashim; Marcela Pekna; Amy Catalfamo; Hsiao-Ying Chin; Foramben Patel; Sravani Rayala; Ketan Shevde; Peter S Heeger; Ming Zhang
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 8.  The complement system in ischemia-reperfusion injuries.

Authors:  William B Gorsuch; Elvina Chrysanthou; Wilhelm J Schwaeble; Gregory L Stahl
Journal:  Immunobiology       Date:  2012-08-07       Impact factor: 3.144

9.  Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction.

Authors:  James E Clark; Thomas Dudler; Michael S Marber; Wilhelm Schwaeble
Journal:  Open Heart       Date:  2018-01-09

Review 10.  Structural and functional diversity of collectins and ficolins and their relationship to disease.

Authors:  Mark Howard; Conrad A Farrar; Steven H Sacks
Journal:  Semin Immunopathol       Date:  2017-09-11       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.